Product portfolio

Companion diagnostics

Your assay choice matters

For every 10 cancer patients treated, an average of only half will benefit. For some, the treatment won’t have any effect; others may suffer from serious side effects.1 In collaboration with leading pharmaceutical companies, we identify and develop innovative predictive diagnostics to target those patients who are more likely to respond to specific therapies.

We help to advance Personalized Healthcare by delivering diagnostic confidence through a broad menu of high medical value assays. Our standardized, fully-automated and easy-to-use solutions enable rapid turnaround time, empowering physicians to make the right patient decisions more quickly.

#1 provider of companion diagnostics, global partner of choice
Over the last decade, Roche has worked with nearly 200 pharmaceutical and biotechnology companies to develop and commercialize predictive assays that help enable patient access to innovative cancer drugs.
From exploratory research through global patient access, we offer a comprehensive range of solutions to support successful IVD assay development and registration – regardless of drug development stage. Our unrivaled experience and unique expertise in bringing companion diagnostics to market helps partners meet their program timelines and bolster probability of success, while our commercial advantage ensures more patients can benefit from novel therapies, more quickly.

Related links

Roche pathologist resources image

Pathologist resources

Our dedicated team of in-house pathologists has developed a variety of educational resources and tools to aid in the interpretation of our assays. Find links to: product information in eLabDoc, the Roche Pathology Education Portal to access our full library of eLearning modules, webinars, cutting-edge research articles and more.

Learn more
PD-L1 SP263 slide and therapy image

The PD-L1 biomarker is transforming tumor testing

Learn more about why the expanding application of this predictive assay is ideal for future-focused labs looking for a sustainable PD-L1 diagnostic solution.

Learn more
PD-L1 SP263 slide and therapy image

Journey of a liquid biopsy

Certain lung cancer patients are not good candidates for tissue biopsy as this is an invasive procedure that carries risk. Liquid biopsy offers a non-invasive alternative for clinicians to identify clinically relevant biomarkers in patients to guide treatment decisions.

Learn more

1. Source: Roche Personalized Healthcare brochure, 2011

Found 0 results in